Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CVRX NASDAQ:DXR NYSE:INFU NASDAQ:INGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVRXCVRx$7.85-0.4%$7.28$4.30▼$18.55$206.08M1.27269,874 shs116,971 shsDXRDaxor$11.00-2.5%$10.01$6.55▼$11.38$54.56M-0.1380,135 shs15,818 shsINFUInfuSystem$10.78+0.5%$7.20$4.61▼$11.04$220.19M1.81176,357 shs314,045 shsINGNInogen$7.99+0.4%$7.04$5.70▼$13.22$216.05M1.72270,789 shs167,360 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVRXCVRx-0.38%+0.64%-4.96%+18.58%-20.95%DXRDaxor-2.48%0.00%+11.11%+35.80%+40.94%INFUInfuSystem+0.47%+12.64%+88.79%+86.51%+66.62%INGNInogen+0.38%+3.10%+21.98%+24.07%-38.44%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCVRXCVRx2.5041 of 5 stars3.41.00.00.03.32.50.6DXRDaxor4.2526 of 5 stars3.55.00.00.03.81.70.0INFUInfuSystem2.6802 of 5 stars1.05.00.00.02.63.32.5INGNInogen4.283 of 5 stars3.35.00.03.92.51.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCVRXCVRx 2.86Moderate Buy$14.0078.34% UpsideDXRDaxor 3.00Buy$25.00127.27% UpsideINFUInfuSystem 4.00Strong Buy$12.5015.96% UpsideINGNInogen 2.50Moderate Buy$11.0037.67% UpsideCurrent Analyst Ratings BreakdownLatest DXR, INGN, INFU, and CVRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/5/2025CVRXCVRxCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$11.007/22/2025INFUInfuSystemRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.007/21/2025INFUInfuSystemRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy7/7/2025CVRXCVRxWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/16/2025INGNInogenB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.006/15/2025INGNInogenB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.00(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCVRXCVRx$54.65M3.76N/AN/A$2.22 per share3.54DXRDaxorN/AN/AN/AN/AN/AN/AINFUInfuSystem$139.89M1.57$0.84 per share12.79$2.47 per share4.36INGNInogen$343.47M0.63N/AN/A$7.38 per share1.08Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCVRXCVRx-$59.97M-$2.10N/AN/AN/A-95.61%-79.31%-40.96%11/4/2025 (Estimated)DXRDaxorN/AN/A0.00∞N/AN/AN/AN/AN/AINFUInfuSystem$870K$0.23179.7034.77N/A1.12%2.78%1.41%N/AINGNInogen-$35.89M-$1.06N/AN/AN/A-7.58%-13.77%-8.52%11/6/2025 (Estimated)Latest DXR, INGN, INFU, and CVRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025INGNInogen-$0.22-$0.15+$0.07-$0.15$90.40 million$92.28 million8/4/2025Q2 2025CVRXCVRx-$0.52-$0.57-$0.05-$0.57$13.22 million$13.59 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCVRXCVRxN/AN/AN/AN/AN/ADXRDaxorN/AN/AN/AN/AN/AINFUInfuSystemN/AN/AN/AN/AN/AINGNInogenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCVRXCVRx0.8511.9910.78DXRDaxorN/AN/AN/AINFUInfuSystem0.501.981.59INGNInogenN/A3.032.67Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCVRXCVRx75.27%DXRDaxor1.34%INFUInfuSystem71.13%INGNInogen89.94%Insider OwnershipCompanyInsider OwnershipCVRXCVRx13.90%DXRDaxor59.50%INFUInfuSystem11.40%INGNInogen1.46%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCVRXCVRx16026.15 million22.52 millionOptionableDXRDaxor374.84 million1.96 millionNot OptionableINFUInfuSystem41020.43 million19.10 millionOptionableINGNInogen1,03027.04 million26.65 millionOptionableDXR, INGN, INFU, and CVRX HeadlinesRecent News About These CompaniesAlphaQuest LLC Raises Stock Holdings in Inogen, Inc $INGNAugust 30 at 4:33 AM | marketbeat.comInogen (NASDAQ:INGN) Share Price Passes Above Fifty Day Moving Average - Should You Sell?August 28 at 4:41 AM | marketbeat.comWall Street Analysts Think Inogen (INGN) Could Surge 49.25%: Read This Before Placing a BetAugust 21, 2025 | zacks.comNeedham Sticks to Its Buy Rating for Inogen (INGN)August 17, 2025 | theglobeandmail.comConnor Clark & Lunn Investment Management Ltd. Increases Position in Inogen, Inc (NASDAQ:INGN)August 16, 2025 | marketbeat.comInogen’s Voxi 5 opens door to larger respiratory care marketAugust 16, 2025 | hmenews.comHInogen (NASDAQ:INGN) Share Price Crosses Above 50 Day Moving Average - What's Next?August 14, 2025 | marketbeat.comXTX Topco Ltd Purchases New Holdings in Inogen, Inc (NASDAQ:INGN)August 14, 2025 | marketbeat.comInogen Inc’s Earnings Call Highlights Growth and InnovationAugust 13, 2025 | msn.comInogen: ‘We are executing a turnaround’August 12, 2025 | hmenews.comHInogen Second Quarter 2025 Earnings: Beats ExpectationsAugust 10, 2025 | finance.yahoo.comInogen Announces Second Quarter 2025 Financial ResultsAugust 9, 2025 | finance.yahoo.comInogen, Inc. (INGN) Q2 2025 Earnings Call TranscriptAugust 8, 2025 | seekingalpha.comInogen Stock Gains Following Q2 Earnings Beat, Revenues Up Y/YAugust 8, 2025 | zacks.comInogen Inc (INGN) Q2 2025 Earnings Call Highlights: Steady Growth Amidst ChallengesAugust 8, 2025 | gurufocus.comInogen (INGN) Reports Q2 Loss, Beats Revenue EstimatesAugust 7, 2025 | zacks.comInogen (INGN) to Release Earnings on ThursdayJuly 31, 2025 | marketbeat.comInogen makes executive appointmentJuly 30, 2025 | hmenews.comHMonaco Asset Management SAM Has $1.20 Million Stock Position in Inogen, Inc (NASDAQ:INGN)July 30, 2025 | marketbeat.comInogen: Earnings Uncertainty Weakens Valuation Argument (Rating Downgrade)July 21, 2025 | seekingalpha.comInogen to Report Second Quarter 2025 Financial Results on August 7, 2025July 17, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 2025An Atomic Sized Surge Is Brewing for NuScale Power Stock PriceBy Thomas Hughes | August 11, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025From Debt to Liftoff: EchoStar's $23 Billion CatalystBy Jeffrey Neal Johnson | August 27, 2025DXR, INGN, INFU, and CVRX Company DescriptionsCVRx NASDAQ:CVRX$7.85 -0.03 (-0.38%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$7.84 -0.01 (-0.19%) As of 08/29/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Daxor NASDAQ:DXR$11.00 -0.28 (-2.48%) As of 08/29/2025 02:32 PM EasternDaxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.InfuSystem NYSE:INFU$10.78 +0.05 (+0.47%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$10.78 0.00 (-0.05%) As of 08/29/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.Inogen NASDAQ:INGN$7.99 +0.03 (+0.38%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$8.00 +0.00 (+0.06%) As of 08/29/2025 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
